Zacks Investment Research upgraded shares of BRENNTAG AG/ADR (OTCMKTS:BNTGY) from a sell rating to a hold rating in a research note published on Wednesday, Zacks.com reports.
According to Zacks, “Brenntag AG engages in the production and distribution of chemicals. It operates through the North America, Latin America, EMEA and Asia Pacific segments. Brenntag AG is headquartered in Mülheim an der Ruhr, Germany. “
Separately, ValuEngine raised shares of BRENNTAG AG/ADR from a sell rating to a hold rating in a report on Friday, March 15th.
BNTGY opened at $9.42 on Wednesday. BRENNTAG AG/ADR has a fifty-two week low of $8.20 and a fifty-two week high of $12.86. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.76 and a quick ratio of 1.21. The firm has a market capitalization of $7.54 billion, a price-to-earnings ratio of 13.46, a PEG ratio of 1.59 and a beta of 1.26.
BRENNTAG AG/ADR (OTCMKTS:BNTGY) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. BRENNTAG AG/ADR had a net margin of 3.61% and a return on equity of 14.00%. The company had revenue of $3.70 billion during the quarter. As a group, equities analysts anticipate that BRENNTAG AG/ADR will post 0.69 EPS for the current year.
The company also recently disclosed an annual dividend, which will be paid on Wednesday, July 3rd. Shareholders of record on Monday, June 17th will be issued a $0.175 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a yield of 1.6%. BRENNTAG AG/ADR’s payout ratio is 24.29%.
BRENNTAG AG/ADR Company Profile
Brenntag AG, a chemical distribution company, purchases and supplies industrial and specialty chemicals in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.
Recommended Story: Short Selling Stocks, A Beginner’s Guide
Get a free copy of the Zacks research report on BRENNTAG AG/ADR (BNTGY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRENNTAG AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRENNTAG AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.